Abstract
This study was designed to evaluate the efficacy and tolerability of recombinant leukocyte interferon alfa-2a (Hoffmann-LaRoche) as single agent in patients with histologically confirmed Mycosis Fungoides. The protocol consisted of a 12 week induction with subcutaneous interferon, escalating from 3 up to 18 million units daily, and a 6 or 9 month maintenance phase for complete or partial responses, respectively, with 18 million units 3 times weekly. 12 patients are evaluable: 5 are in complete remissions, 6 are partial remissions, and one had disease progression. Alfa-2a interferon was well tolerated: only 3 patients had WHO grade IV organ toxicity. Our study documents that recombinant leukocyte alfa 2a is a highly active agent in untreated patients with Mycosis Fungoides. Finally, the dose schedule chosen in this study allows alfa-2a interferon administration on an outpatient basis.
Original language | English |
---|---|
Pages (from-to) | 93-99 |
Number of pages | 7 |
Journal | Journal of Biological Regulators and Homeostatic Agents |
Volume | 1 |
Issue number | 2 |
Publication status | Published - Apr 1987 |
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Endocrinology
- Physiology
- Immunology
- Medicine (miscellaneous)
- Endocrinology, Diabetes and Metabolism
- Physiology (medical)